On June 3, 2025, the pharmaceutical company Sanofi signed Memoranda of Understanding with the Private Higher Education Institution Dobrobut Academy and the Dobrobut Medical Network. The partnership aims to significantly improve patient access in Ukraine to innovative methods for the diagnosis and treatment of orphan diseases, cardiovascular diseases, diabetes mellitus, and to improve the level of immunoprophylaxis.
In particular, the partners are joining forces within the Orphan Diseases Academy project, which aims to detect rare hereditary diseases at an early stage and provide comprehensive support to patients, including through free access to highly specialized laboratory diagnostics abroad.
Another important area of cooperation is the development of preventive and educational programs on diabetes and cardiovascular diseases, as well as the organization of training courses and workshops for medical professionals using modern methods and experts. This contributes to improving the professional level of doctors and introducing advanced technologies into medical practice.
Particular attention is paid to the introduction of digital solutions for patient monitoring and the active promotion of vaccination as a key tool for protecting public health, which contributes to strengthening immunoprophylaxis and increasing vaccination literacy.
“At a time when Ukraine’s healthcare system is facing unprecedented challenges, reliable partnerships are crucial. We are delighted that new partners are joining Sanofi’s educational initiatives – the Dobrobut medical network and the Dobrobut Academy, leading medical institutions that share our values of quality, accessibility, and trust. Working together on early diagnosis, training healthcare professionals, introducing innovative technologies, and strengthening immunoprophylaxis will expand the possibilities for helping patients and reinforce our common goal of providing Ukrainians with adequate support regardless of their circumstances,” said Olena Bushmina, Head of the Pharmaceutical Division at Sanofi in Ukraine.
“I am very pleased that two leading healthcare companies, Dobrobut and Sanofi, have signed a memorandum. After all, we are talking about concrete actions for the health of Ukrainians. Our cooperation will provide hundreds of patients with orphan, endocrinological, and cardiovascular diseases with access to the best modern diagnostics and necessary knowledge. I have no doubt that our joint efforts will bear fruit: a better quality of life and hope for those who need support, said Serhiy Orel, CEO of the Dobrobut medical network.
“At a time when every initiative can save lives, joining forces is not just important — it is vital. For the Dobrobut Academy, this partnership is not just about education. It is about hope for patients, new horizons for doctors, and the belief that even in the most difficult times, we can build a future together. We are proud to be part of this great cause,” said Nana Voitenko, rector of the Dobrobut Academy, professor, and doctor of biological sciences.
The cooperation agreement was signed at the Dobrobut Academy, a private higher education institution, with the participation of Olena Bushmina, Head of the Pharmaceutical Division at Sanofi Ukraine, Serhii Orla, CEO of the Dobrobut Medical Network, and Nana Voitenko, Rector of the Dobrobut Academy.
